Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.
In: Cancer Immunology, Immunotherapy, Jg. 64 (2015-12-01), Heft 12, S. 1609-1621
Online
academicJournal
Zugriff:
We have previously reported two trials in non-small cell lung cancer (NSCLC) evaluating vaccine therapy with the telomerase peptide GV1001. The studies demonstrated considerable differences in survival among immune responders, highlighting that an immune response is not necessarily beneficial. In the present study, we conducted long-term clinical follow-up and investigated immunological factors hypothesized to influence clinical efficacy. Peripheral blood mononuclear cells from 33 NSCLC trial patients and 15 healthy donors were analyzed by flow cytometry for T regulatory cells (Tregs, CD4CD25CD127FOXP3) and two types of myeloid-derived suppressor cells (MDSCs, HLA- DR CD14 or Lin HLA- DR CD33 CD11b). T cell cultures were analyzed for 17 cytokines. The results demonstrated that immune responders had increased overall survival (OS, p < 0.001) and progression-free survival ( p = 0.003), compared to subjects without immunological response. The mean OS advantage was 54 versus 13 months. Six patients were still alive at the last clinical update, all belonging to the immune responders. No serious toxicity had developed (maximum observation 13 years). Most patients developed a polyfunctional cytokine profile, with high IFNγ/IL-4 and IFNγ/IL-10 ratios. Low Treg levels were associated with improved OS ( p = 0.037) and a favorable cytokine profile, including higher IFNγ/IL-10 ratios. High CD33 MDSC levels were associated with poorer immune response rate ( p = 0.005). The levels of CD14 MDSC were significantly higher in patients than in healthy controls ( p = 0.012). We conclude that a randomized GV1001 trial in NSCLC is warranted. The findings suggest that Tregs and MDSCs are associated with a tolerogenic cytokine milieu and impaired clinical efficacy of vaccine responses. [ABSTRACT FROM AUTHOR]
Copyright of Cancer Immunology, Immunotherapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.
|
---|---|
Autor/in / Beteiligte Person: | Hansen, Gaute ; Gaudernack, Gustav ; Brunsvig, Paal ; Cvancarova, Milada ; Kyte, Jon |
Link: | |
Zeitschrift: | Cancer Immunology, Immunotherapy, Jg. 64 (2015-12-01), Heft 12, S. 1609-1621 |
Veröffentlichung: | 2015 |
Medientyp: | academicJournal |
ISSN: | 0340-7004 (print) |
DOI: | 10.1007/s00262-015-1766-5 |
Schlagwort: |
|
Sonstiges: |
|